Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib

Abstract Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. A better understanding of expected outcomes in these patients is necessary to establish a benchmark for evaluating novel agents...

Full description

Bibliographic Details
Main Authors: Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Wei Ding, Jose F. Leis, Asher A. Chanan-Khan, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Sikander Ailawadhi, Amber B. Koehler, Ricardo Parrondo, Susan M. Schwager, Taimur Sher, Curtis A. Hanson, Min Shi, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh
Format: Article
Language:English
Published: Nature Publishing Group 2022-09-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00721-6

Internet

https://doi.org/10.1038/s41408-022-00721-6

Similar Items